Aurobindo Pharma board approves to transfer Biosimilars biz for Rs361.46 cr - (India Infoline via NewsPoints Desk)

  • Aubindo's board members have approved its proposal to transfer biosimilars and its related R&D and manufacturing facilities, reported India Infoline.

  • Specifically, the company will transfer its biosimilars business to another wholly-owned subsidiary, CuraTeQ Biologics, for a cash consideration of INR361.46 crore.

  • CuraTeO was incorporated by Aurobindo on April 25 to carry the business of R&D in recombinant biologics product development, especially in areas of biosimilars drug substance development, proteins formulations, and commercialisation of products of its own or third party, the news source said.

To read more NewsPoints articles, click here.